Europe Endoscopic Hemostasis Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
675.69 Million
USD
1,183.22 Million
2025
2033
 Período de previsão |
2026 –2033 |
 Tamanho do mercado (ano base ) | USD 675.69 Million |
 Tamanho do mercado ( Ano de previsão) | USD 1,183.22 Million |
 CAGR |
% |
| Principais participantes do mercado |
|
Europe Endoscopic Hemostasis Market, By Product Type (Mechanical Hemostasis Devices, Thermal Devices, Topical Agents and Injectables, and Others), Procedure (Upper Gastrointestinal Endoscopy, Lower Gastrointestinal Endoscopy, Bronchoscopic Hemostasis, and Others), Application (Gastrointestinal Bleeding, Non-Gastrointestinal Bleeding, Trauma Management, and Others), End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others), Distribution Channel (Direct Sales and Indirect Sales) - Industry Trends and Forecast to 2033
Europe Endoscopic Hemostasis Market Size
- The Europe endoscopic hemostasis market is expected to reach USD 1,183.22 million by 2033 from USD 675.69 million in 2025, growing with a substantial CAGR of 7.7% in the forecast period of 2026 to 2033
- The Europe endoscopic hemostasis market is witnessing steady and robust growth, driven by the rising prevalence of gastrointestinal disorders, increasing incidence of colorectal cancer, peptic ulcers, and gastrointestinal bleeding, and the growing adoption of minimally invasive endoscopic procedures across the region..
- Market growth is further supported by stringent clinical guidelines, a strong focus on patient safety and procedural efficacy, and rising demand for advanced hemostatic technologies that improve procedural outcomes and reduce complication rates. Continuous advancements in endoscopic device design, including improved clips, coagulation systems, sprays, and combination therapies, are enhancing precision, ease of use, and clinical effectiveness.
Europe Endoscopic Hemostasis Market Analysis
- Endoscopic Hemostasis products are becoming increasingly critical across the Europe healthcare ecosystem, enabling clinicians to effectively manage gastrointestinal bleeding during diagnostic and therapeutic endoscopic procedures. These devices play a vital role in improving procedural safety, clinical outcomes, and patient recovery by ensuring rapid and reliable bleeding control. Endoscopic hemostasis solutions are widely used across key clinical settings, including hospitals, specialty clinics, and ambulatory surgical centers, for applications such as peptic ulcer bleeding, colorectal procedures, post-polypectomy bleeding, and tumor-related hemorrhage.
- Expanding healthcare infrastructure, rising volumes of endoscopic procedures, and increasing adoption of minimally invasive treatment approaches are fueling strong demand for endoscopic hemostasis devices in Europe. Healthcare providers are increasingly incorporating advanced hemostatic technologies to improve procedural efficiency, reduce complication rates, shorten hospital stays, and enhance overall patient outcomes, thereby supporting sustained market growth.
- Additionally, stringent clinical guidelines, increasing emphasis on patient safety, and growing regulatory scrutiny are accelerating the adoption of advanced and clinically proven endoscopic hemostasis solutions. Medical device manufacturers are investing heavily in R&D to develop innovative products that offer improved precision, ease of use, and compatibility with modern endoscopic platforms, while meeting evolving regulatory standards and clinical performance requirements.
- Germany is projected to lead the Europe endoscopic hemostasis market in 2026, accounting for 15.89% of the regional market share. This leadership is supported by the country’s well-established healthcare infrastructure, high volume of endoscopic procedures, strong adoption of advanced medical technologies, and presence of leading medical device manufacturers. Favorable reimbursement frameworks, a skilled clinical workforce, and continuous investments in healthcare innovation further strengthen Germany’s dominant position within the European market.
- Denmark is the fastest-growing country in the Europe endoscopic hemostasis market, supported by early adoption of digital health and advanced endoscopy platforms, strong integration of AI-assisted diagnostics and image-guided endoscopic procedures, and a high level of clinical research participation in gastrointestinal and interventional endoscopy. The country’s well-structured referral pathways, emphasis on day-care and outpatient endoscopic treatments, and rapid commercial uptake of next-generation hemostatic devices by clinicians further accelerate procedural volumes. In addition, collaborations between hospitals, academic institutions, and medical device manufacturers, along with streamlined regulatory approval timelines for innovative technologies, continue to position Denmark as a leading early-adopter market, driving faster growth compared to other European countries.
- The Mechanical Hemostasis Devices segment is dominating the Europe Endoscopic Hemostasis Market, accounting for 43.86% market share in 2025. This dominance is driven by the widespread clinical adoption of endoscopic clips and band ligation devices due to their proven efficacy, ease of deployment, cost-effectiveness, and suitability for a broad range of gastrointestinal bleeding indications. Their strong safety profile and compatibility with standard endoscopic procedures continue to support sustained demand across healthcare settings.
Report Scope and Europe Endoscopic Hemostasis Market Segmentation
|
Attributes |
Europe Endoscopic Hemostasis Market Insights |
|
Segments Covered |
|
|
Countries Covered |
Europe
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include Vendor Selection Criteria, Technological Advancement, Patent Analysis, regulatory framework, Innovation Tracker and strategic analysis Tariffs and Impact on the market. |
Europe Endoscopic Hemostasis Market Trends
Increasing Adoption of Advanced Minimally Invasive Endoscopic Hemostasis Technologies
- The steady expansion of endoscopic and minimally invasive procedures across Europe is a major factor driving the increased adoption of endoscopic hemostasis devices. As the incidence of gastrointestinal bleeding, colorectal disorders, and related conditions continues to rise, healthcare providers increasingly rely on advanced hemostasis solutions to ensure effective bleeding control, procedural safety, and improved patient outcomes across high-volume clinical environments.
- Endoscopic hemostasis devices play a critical role in ensuring clinical efficacy, patient safety, and procedural reliability throughout diagnostic and therapeutic endoscopy. By enabling rapid bleeding control, reducing complication risks, and supporting minimally invasive treatment approaches, these devices help optimize procedural workflows while improving recovery times and overall quality of care across healthcare facilities.
- The growing adoption of advanced endoscopic technologies, including high-definition imaging, therapeutic endoscopy, and combination hemostasis techniques, has increased demand for high-performance hemostatic solutions. Innovations in mechanical clips, thermal coagulation systems, injection therapies, and topical hemostatic agents are enhancing procedural precision, treatment success rates, and clinician confidence while supporting evolving clinical practices.
- Healthcare providers across the care continuum are increasingly adopting endoscopic hemostasis devices to meet rising regulatory, safety, and clinical performance standards. Stringent clinical guidelines, growing emphasis on patient safety and outcome-based care, and increasing demand for minimally invasive interventions are encouraging hospitals and clinics to integrate advanced hemostasis technologies that ensure consistency, compliance, and high-quality care delivery.
- Overall, the expanding scale of endoscopic procedures, clinical innovation, and healthcare infrastructure development positions endoscopic hemostasis devices as an essential component of modern gastrointestinal care. These solutions support procedural efficiency, patient safety, regulatory compliance, and sustainable growth across Europe’s evolving endoscopy landscape, making this insight readily reusable across regions by adapting healthcare system dynamics and adoption patterns.
Europe Endoscopic Hemostasis Market Dynamics
Driver
Rise in Gastrointestinal Bleeding Cases
- The rising incidence of gastrointestinal bleeding has been established as a foundational force propelling growth in the global endoscopic hemostasis market. As the prevalence of upper and lower gastrointestinal bleeding conditions increases worldwide, demand for minimally invasive, endoscopy-based therapeutic interventions has been intensified. Endoscopic hemostasis offers critical clinical advantages, including rapid bleeding control, reduced need for surgical intervention, lower transfusion requirements, and shorter hospital stays, thereby positioning it as a first-line treatment modality in acute and chronic gastrointestinal bleeding management. Consequently, the escalation in gastrointestinal bleeding cases—driven by aging populations, higher prevalence of liver disease, anticoagulant use, and delayed care access during systemic healthcare disruptions—has translated into higher procedural volumes and broader adoption of advanced endoscopic hemostasis devices across hospitals and endoscopy centers globally.
- For instances,
- In September 2021, Medscape reported that upper gastrointestinal bleeding occurred at an incidence of approximately 100 cases per 100,000 population annually and remained one of the most common causes of emergency hospital admissions, underscoring a persistently high disease burden requiring endoscopic intervention.
- In June2023, Gastroenterology Research journal reported that mortality related to upper gastrointestinal bleeding in the U.S. increased between 2012 and 2021, with steeper increases observed toward the later years, indicating worsening clinical outcomes and intensified treatment requirements.
- In June 2023, StatPearls Publishing stated that gastrointestinal bleeding continues to represent a frequent global medical emergency, with urgent endoscopic diagnosis and hemostatic treatment remaining critical to reducing mortality and morbidity.
- In January 2025, the Journal of Clinical Medicine reported that patients with advanced liver disease exhibited significantly higher incidence of massive gastrointestinal bleeding episodes, reinforcing the link between chronic disease prevalence and increased need for endoscopic hemostasis.
- In September 2025, PubMed Central highlighted that upper gastrointestinal bleeding remained a life-threatening complication among chronic liver disease populations, sustaining elevated demand for endoscopic therapeutic procedures.
- The global escalation in gastrointestinal bleeding incidence is being firmly established as a permanent structural growth engine for the endoscopic hemostasis market. The continuous rise in acute bleeding events, combined with expanding populations affected by chronic liver disease, antithrombotic medication use, and age-related gastrointestinal pathology, is creating a sustained and non-cyclical requirement for endoscopic bleeding control. As clinical guidelines increasingly prioritize endoscopic therapy as first-line management, reliance on hemostasis technologies for emergency intervention, recurrence prevention, and complication management is being structurally reinforced. Furthermore, improving survival rates are extending patient monitoring and repeat intervention cycles, thereby multiplying lifetime procedural demand. This dynamic is anchoring endoscopic hemostasis adoption closely to global epidemiological trends, positioning this driver as a long-term foundational pillar for market expansion across developed and emerging healthcare systems.
Restraint/Challenge
High Cost and Technical Complexity of Endoscopic Hemostasis Devices
- Despite growing clinical adoption, the Europe endoscopic hemostasis market continues to face structural restraint due to the high cost and technical complexity of advanced endoscopic hemostasis devices. These technologies often require significant upfront capital investment for equipment procurement, continuous expenditure on consumables, and specialized maintenance. In addition, effective use of hemostatic endoscopic devices demands advanced physician training, skilled support staff, and sophisticated hospital infrastructure, limiting adoption in cost-sensitive healthcare systems. Public hospitals in low- and middle-income countries, and even budget-constrained facilities in developed regions, frequently encounter barriers related to affordability, reimbursement gaps, and workforce readiness. As a result, uneven access and slower penetration of advanced endoscopic hemostasis technologies persist, constraining broader market expansion.
- For Instance,
- In November 2022, according to the high cost of gastrointestinal endoscopy procedures and equipment is a major restraint. For example, TNE costs Euro 125.90 per procedure, while oral endoscopy costs Euro 184.10 and MACE costs Euro 407.10. Additionally, equipment maintenance and reprocessing add to the cost, with flexible endoscopes costing around Euro 79,330, making procedures expensive overall.
- In June 2024, Science direct highlighted that the high cost of gastrointestinal endoscopy is exacerbated in low-income and middle-income countries (LICs and LMICs) due to the lack of local maintenance and repair facilities. Scopes requiring repairs must be shipped abroad, incurring significant costs and delays. Additionally, cheaper second-hand and Chinese-manufactured endoscopes often lack adequate service and maintenance support.
- In October 2025, BMJ Open Gastroenterology published a micro-costing study showing that in a UK National Health Service hospital, the total per-procedure cost of reusable gastrointestinal endoscopes was an estimated GBP107.34, with capital and maintenance costs as major cost drivers, highlighting economic barriers to wide adoption of endoscopic equipment in public health settings.
- In August 2024, a ScienceDirect narrative review reported that purchase, maintenance, and associated logistics costs of endoscopy equipment remain a major barrier to developing and sustaining endoscopy services in low- and middle-income countries, due to high device cost and lack of infrastructure.
- In February 2025, as per science direct the high cost of gastrointestinal endoscopy is evident in various studies, especially for screening and surveillance. For instance, while general population screenings may not be cost-effective in Western regions, targeted surveillance for high-risk groups, such as those with gastric intestinal metaplasia, can still be cost-effective, with ICERs ranging from USD 20,739.1 to 98,402.2 per QALY.
- The compiled evidence clearly indicates that the high cost and technical complexity associated with gastrointestinal endoscopy and endoscopic hemostasis devices represent a persistent restraint on market growth. Substantial capital investment for equipment procurement, elevated per-procedure costs, and ongoing expenses related to maintenance, reprocessing, and repair significantly increase the overall cost burden on healthcare systems. These challenges are further intensified in low- and middle-income regions where limited technical infrastructure and lack of local servicing capabilities delay adoption and restrict procedural capacity. Even in developed healthcare systems, cost-effectiveness considerations influence screening strategies and limit widespread implementation. Collectively, these economic and operational constraints slow penetration of advanced endoscopic hemostasis technologies, reinforcing affordability and technical complexity as structural barriers to broader market expansion
Europe Endoscopic Hemostasis Market Scope
The Europe endoscopic hemostasis market is categorized into five key segments: product type, procedure, application, end user, and distribution channel.
- By product type
On the basis of product type, the Europe endoscopic hemostasis market is segmented into mechanical hemostasis devices, thermal devices, topical agents and injectables, and others. In 2026, the mechanical hemostasis devices segment is projected to dominate the Europe endoscopic hemostasis market with the largest market share of 43.89%, owing to its widespread clinical preference for achieving immediate, controlled, and durable bleeding cessation during endoscopic interventions. Mechanical solutions such as clips and banding devices are routinely favored for their ability to provide precise vessel closure without inducing thermal tissue damage, thereby lowering rebleeding rates and post-procedure complications. Their applicability across a broad spectrum of bleeding scenarios, including peptic ulcers, variceal hemorrhage, and post-polypectomy bleeding, has resulted in consistently high utilization in both emergency and elective endoscopic settings. The strong reliance on mechanical hemostasis as a first-line therapeutic approach underscores its substantial contribution to overall market revenues and reinforces its dominant position within the product type landscape throughout the forecast period.
The topical agents and injectables segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.1%. This growth is primarily driven by the rising incidence of gastrointestinal (GI) bleeding disorders, increasing adoption of minimally invasive endoscopic procedures, and the clinical preference for fast-acting, easy-to-apply hemostatic solutions during emergency and elective interventions.
- By procedure
On the basis of procedure, the market is segmented into upper gastrointestinal endoscopy, lower gastrointestinal endoscopy, bronchoscopic hemostasis, and others. In 2026, the upper gastrointestinal endoscopy segment is projected to dominate the Europe endoscopic hemostasis market with a market share of 43.62%, due to its extensive clinical adoption as the frontline procedural approach for managing acute and recurrent gastrointestinal bleeding. Upper GI endoscopy is widely relied upon for the diagnosis and immediate therapeutic control of bleeding ulcers, variceal hemorrhage, and Dieulafoy lesions, where rapid hemostatic intervention is clinically critical. The high procedural frequency in emergency departments and tertiary-care hospitals, combined with strong guideline support for early endoscopic intervention, is expected to sustain its leading market position. Its continued dominance is reflected in its substantial market share and steady growth trajectory through 2033, indicating persistent demand across both developed and emerging healthcare systems.
The lower gastrointestinal endoscopy segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.1%. This growth is driven by the rising prevalence of lower gastrointestinal bleeding conditions, including colorectal cancer, inflammatory bowel disease, diverticular disease, and hemorrhoidal bleeding, along with increasing adoption of screening and diagnostic colonoscopy procedures across Europe.
- By application
On the basis of application, the market is segmented into gastrointestinal bleeding, non-gastrointestinal bleeding, trauma management, and others. In 2026, the gastrointestinal bleeding segment is projected to dominate the Europe endoscopic hemostasis market with a market share of 71.57%, owing to the high global prevalence of peptic ulcers, esophageal varices, and colorectal malignancies requiring endoscopic bleeding control. Gastrointestinal bleeding remains the most common indication for endoscopic hemostasis procedures, driving consistent utilization of mechanical, thermal, and topical hemostatic solutions across hospital and ambulatory care settings. The critical need for rapid bleeding control to reduce morbidity, hospital length of stay, and mortality is expected to reinforce sustained demand within this application segment. Its large share of total market value highlights the central role of gastrointestinal indications in shaping overall market dynamics during the forecast period.
The trauma management segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.3%. This growth is driven by the increasing incidence of traumatic injuries, including abdominal trauma, accidental injuries, and emergency gastrointestinal bleeding cases, along with the rising preference for minimally invasive endoscopic interventions to achieve rapid bleeding control.
- By end user
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, specialty clinics, and others. In 2026, the hospitals segment is projected to dominate the Europe endoscopic hemostasis market with the largest market share of 52.69%, due to the concentration of advanced endoscopy infrastructure, skilled gastroenterologists, and emergency care capabilities within hospital settings. Complex bleeding cases, including severe upper and lower gastrointestinal hemorrhage, are predominantly managed in public and private hospitals where comprehensive diagnostic and interventional resources are available. Higher patient inflow, greater procedural volumes, and established procurement frameworks further strengthen hospital demand for endoscopic hemostasis devices and consumables. This structural dependence on hospital-based care is expected to maintain the segment’s leading position through 2033 despite gradual growth in outpatient settings.
The ambulatory surgery centers segment is the fastest-growing segment in the Europe endoscopic hemostasis market, registering a CAGR of 8.1%. This growth is driven by the shift of endoscopic procedures from hospitals to outpatient settings, increasing demand for cost-effective and minimally invasive interventions, and the rising adoption of same-day diagnostic and therapeutic endoscopy across Europe.
- By distribution channel
On the basis of distribution channel, the market is segmented into direct sales and indirect sales, with indirect sales further segmented into online and offline channels. In 2026, the indirect sales segment is projected to dominate the Europe endoscopic hemostasis market with the largest market share of 58.48% as procurement is largely conducted through distributors, group purchasing organizations, and regional medical supply networks. Indirect channels are widely preferred due to their ability to offer bundled products, inventory management support, and broader geographic reach, particularly in emerging markets and decentralized healthcare systems. Hospitals and ambulatory centers frequently rely on distributor-led sourcing to ensure consistent availability of critical hemostasis devices while optimizing procurement costs. This distribution structure is expected to continue driving higher adoption of indirect sales channels throughout the forecast period.
The indirect sales segment is the fastest-growing distribution channel in the Europe endoscopic hemostasis market, registering a CAGR of 7.9%. This growth is driven by the expanding role of third-party distributors, group purchasing organizations (GPOs), and regional medical device suppliers in improving market access across diverse European healthcare systems.
Europe Endoscopic Hemostasis Market Regional Analysis
- Germany represents one of the most important markets for endoscopic hemostasis devices, supported by its advanced healthcare infrastructure, strong medical device manufacturing base, and high adoption of minimally invasive endoscopic procedures. Continuous clinical innovation in gastroenterology, a high volume of diagnostic and therapeutic endoscopies, and strict clinical and regulatory standards are driving steady adoption of advanced mechanical, thermal, and topical hemostasis solutions across hospitals and specialty care centers.
- The U.K. is witnessing growing demand for endoscopic hemostasis technologies as increasing prevalence of gastrointestinal disorders, an aging population, and rising emphasis on minimally invasive treatment approaches reshape clinical practice. Healthcare providers are increasingly focused on improving patient safety, reducing procedure-related complications, and enhancing clinical efficiency, which is accelerating the adoption of reliable and cost-effective hemostasis devices across public and private healthcare settings.
- France continues to emerge as a key growth hub for the endoscopic hemostasis market, driven by strong clinical expertise in gastroenterology, expanding access to advanced endoscopic services, and increasing focus on patient-centered and outcome-driven care. The country’s emphasis on clinical quality, safety, and technological innovation is encouraging healthcare institutions to adopt advanced hemostasis solutions that improve procedural outcomes, support minimally invasive interventions, and comply with evolving regulatory and healthcare standards.
Germany Endoscopic Hemostasis Market Insight
The Germany Endoscopic Hemostasis Market is gaining strong traction due to the country’s high volume of gastrointestinal endoscopic procedures and early adoption of advanced therapeutic endoscopy techniques. German hospitals and specialty clinics place strong emphasis on clinical precision, procedural reliability, and evidence-based device selection, driving consistent demand for high-performance mechanical and energy-based hemostasis solutions. In addition, the presence of leading medical device manufacturers, well-established clinical training programs, and strict regulatory and quality standards is fostering rapid uptake of technologically advanced hemostasis devices. Germany’s focus on procedural standardization, patient safety, and outcome optimization reinforces its position as a technology-led and innovation-driven market within Europe.
U.K. Endoscopic Hemostasis Market Insight
The U.K. Endoscopic Hemostasis Market continues to expand as healthcare providers prioritize minimally invasive treatment pathways, efficiency in endoscopy units, and reduction of procedure-related complications. Rising incidence of gastrointestinal bleeding conditions, combined with increasing demand on NHS endoscopy services, is accelerating adoption of cost-effective, easy-to-use hemostasis devices that support high procedural throughput. Strong emphasis on clinical guidelines, value-based care, and standardized treatment protocols is shaping purchasing decisions, while growing use of ambulatory and day-care endoscopy settings is further supporting demand. These factors collectively position the U.K. market as one driven by access, efficiency, and scalable clinical adoption rather than device manufacturing concentration.
Europe Endoscopic Hemostasis Market Share
The Specialty Food Ingredients industry is primarily led by well-established companies, including:
- Micro-Tech Endoscopy (China)
- Taewoong Medical Co., Ltd. (South Korea)
- Ovesco Endoscopy AG (Germany)
- Apollo Endosurgery, Inc. (U.S.)
- Argon Medical Devices, Inc. (U.S.)
- Olympus Corporation (Japan)
- Boston Scientific Corporation (U.S.)
- CONMED Corporation (U.S.)
- Medtronic (Ireland)
- Cook (U.S.)
- ERBE Elektromedizin GmbH (Germany)
- Karl Storz SE & Co. KG (Germany)
- Pentax Medical (Japan)
- Endoskopie Technik Gerhard (Germany)
- Merit Medical Systems, Inc. (U.S.)
- Diversatek, Inc. (U.S.)
- STERIS plc (U.K.)
- B. Braun SE (Germany)
- Duomed Group (Belgium)
Latest Developments in the Europe endoscopic hemostasis market
- In December 2025, Olympus tripled its corporate venture capital fund commitment by launching Olympus Innovation Ventures Fund II with an additional $150 million to invest in MedTech startups focused on endoscopy, diagnostics, digital health, and related innovation fields to reinforce long-term growth and technological leadership.
- In October 2025, Boston Scientific announced an agreement to acquire Nalu Medical, Inc., a privately held medical device company focused on implantable neurostimulation technologies for chronic pain. The acquisition was positioned to strengthen Boston Scientific’s neuromodulation portfolio, accelerate innovation in pain management, and expand treatment options for patients with chronic pain conditions.
- In October 2025, CONMED Corporation announced a strategic exit from its gastroenterology business, divesting its GI product lines and related assets as part of a portfolio realignment to concentrate on core surgical and orthopaedic solutions. The move was positioned to streamline the company’s product focus, sharpen investment in high-growth procedural areas, and improve long-term revenue and margin profiles by reallocating resources toward CONMED’s flagship device platforms and emerging technologies.
- In August 2025, the U.S. Food and Drug Administration (FDA) approved the first-of-its-kind IDE clinical study of Cook Medical’s ADVANCE EVERO 18 everolimus-coated PTA balloon catheter, enabling evaluation of its safety and effectiveness in treating symptomatic peripheral arterial disease. The decision marked a milestone for drug-coated balloon technology, supporting Cook’s advancement of next-generation endovascular therapies aimed at reducing restenosis and improving long-term vessel patency in patients with lower-extremity arterial disease..
- In July, ESGE guidelines on topical hemostatic agents reported Ankaferd Blood Stopper with 73%-100% hemostasis rates for GI bleeding sources such as peptic ulcers and malignancies in endoscopic use..
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES ANALYSIS
4.2 BRAND OUTLOOK
4.2.1 BRAND COMPARATIVE ANALYSIS OF KEY EUROPE PLAYERS
4.2.1.1 BRAND COMPARATIVE NARRATIVE (ANALYTICAL OVERVIEW)
4.2.2 PRODUCT VS BRAND OVERVIEW — EUROPE ENDOSCOPIC HEMOSTASIS MARKET
4.2.2.1 PRODUCT OVERVIEW — ENDOSCOPIC HEMOSTASIS DEVICES
4.2.2.2 BRAND OVERVIEW — INFLUENCE ON EUROPE CLINICAL ADOPTION
4.3 CONSUMER BUYING BEHAVIOUR
4.3.1 CLINICAL EFFECTIVENESS AND PATIENT OUTCOMES
4.3.2 COST AND VALUE CONSIDERATIONS
4.3.3 COMPATIBILITY AND INTEGRATION
4.3.4 TRAINING REQUIREMENTS AND EASE OF USE
4.3.5 REIMBURSEMENT AND HEALTHCARE POLICY ALIGNMENT
4.3.6 PROCUREMENT PROCESSES AND BULK AGREEMENTS
4.3.7 INFLUENCE OF CLINICAL STAKEHOLDERS
4.3.8 TRENDS IN BUYER BEHAVIOUR
4.3.9 CONCLUSION
4.4 PATENT ANALYSIS
4.4.1 PATENT QUALITY AND STRENGTH – EUROPE ENDOSCOPIC HEMOSTASIS MARKET
4.4.2 COUNTRY PATENT LANDSCAPE
4.4.3 IP STRATEGY AND MANAGEMENT
4.4.4 LICENSING AND COLLABORATION
4.5 RAW MATERIAL COVERAGE
4.5.1 METALLIC COMPONENTS AND ALLOY SYSTEMS
4.5.2 POLYMERIC AND SYNTHETIC MATERIALS
4.5.3 NATURAL AND BIOCOMPATIBLE MATERIALS
4.5.4 ELECTRICAL AND THERMAL MATERIAL SYSTEMS
4.5.5 EXPENDABLE ACCESSORIES AND SINGLE-USE MATERIALS
4.6 TECHNOLOGICAL ADVANCEMENTS IN EUROPE ENDOSCOPIC HEMOSTASIS MARKET
4.6.1 ENHANCED MECHANICAL HEMOSTASIS TOOLS
4.6.2 ADVANCED THERMAL COAGULATION AND ENERGY-BASED SYSTEMS
4.6.3 NOVEL TOPICAL HEMOSTATIC AGENTS
4.6.4 INTEGRATION WITH ADJUNCTIVE DIAGNOSTIC TECHNOLOGIES
4.6.5 DEVELOPMENT OF MULTIFUNCTIONAL AND COMBINATION DEVICES
4.6.6 IMPROVED USER ERGONOMICS AND DEVICE DEPLOYMENT SYSTEMS
4.6.7 CONCLUSION
4.7 VALUE CHAIN ANALYSIS
4.7.1 OVERVIEW
4.7.2 RAW MATERIALS & COMPONENTS
4.7.3 DEVICE DESIGN, R&D & MANUFACTURING
4.7.4 PROCESSING, FINISHING & STERILIZATION
4.7.5 PACKAGING & LABELING
4.7.6 LOGISTICS, DISTRIBUTION & COMMERCIALIZATION
4.7.7 CONCLUSION
4.8 VENDOR SELECTION CRITERIA
4.8.1 CLINICAL PERFORMANCE
4.8.2 REGULATORY COMPLIANCE AND APPROVALS
4.8.3 COST AND TOTAL VALUE PROPOSITION
4.8.4 SUPPLY CHAIN ROBUSTNESS AND LOGISTICS
4.8.5 SUPPORT, TRAINING AND CLINICAL EDUCATION
4.8.6 QUALITY SYSTEMS AND REPROCESSING GUIDANCE
4.8.7 REPUTATION, PEER ACCEPTANCE AND POST-MARKET PERFORMANCE
4.8.8 INNOVATION AND FUTURE-READINESS
4.9 COMPANY EVALUATION QUADRANT
4.1 PROFIT MARGIN SCENARIO
4.10.1 MARGIN IMPROVEMENT DRIVERS
4.10.2 COST PRESSURE
4.10.3 REGIONAL VARIATIONS
4.10.4 FUTURE SCENARIOS
4.11 CLIMATE CHANGE SCENARIO
4.11.1 ENVIRONMENTAL CONCERNS
4.11.2 INDUSTRY RESPONSE
4.11.3 GOVERNMENT’S ROLE
4.11.4 ANALYST RECOMMENDATIONS
4.12 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.12.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.12.1.1 JOINT VENTURES
4.12.1.2 MERGERS AND ACQUISITIONS
4.12.1.3 LICENSING AND PARTNERSHIP
4.12.1.4 TECHNOLOGY COLLABORATIONS
4.12.2 STRATEGIC DIVESTMENTS
4.12.3 STAGE OF DEVELOPMENT
4.12.4 TIMELINES AND MILESTONES
4.12.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.12.6 RISK ASSESSMENT AND MITIGATION
4.12.7 FUTURE OUTLOOK
4.13 PRICING ANALYSIS
4.13.1 HEMOSTATIC CLIPS AND FORCEPS PRICING
4.13.2 BANDING AND COAGULATION DEVICES
4.13.3 REGULATORY AND REIMBURSEMENT IMPACT
4.14 SUPPLY CHAIN ANALYSIS
4.14.1 OVERVIEW
4.14.2 LOGISTIC COST SCENARIO
4.14.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
4.14.4 CONCLUSION
5 TARIFFS & IMPACT ON THE MARKET
5.1 OVERVIEW
5.2 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS
5.3 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE
5.4 VENDOR SELECTION CRITERIA
5.5 IMPACT ON SUPPLY CHAIN
5.5.1 RAW MATERIAL PROCUREMENT
5.5.2 MANUFACTURING AND PRODUCTION
5.5.3 LOGISTICS AND DISTRIBUTION
5.5.4 PRICE PITCHING AND POSITION OF MARKET
5.6 INDUSTRY PARTICIPANTS: PROACTIVE MOVES
5.6.1 SUPPLY CHAIN OPTIMIZATION
5.6.2 JOINT VENTURE ESTABLISHMENTS
5.7 IMPACT ON PRICES
5.8 REGULATORY INCLINATION
5.8.1 GEOPOLITICAL SITUATION
5.8.2 TRADE PARTNERSHIPS BETWEEN THE COUNTRIES
5.8.2.1 FREE TRADE AGREEMENTS
5.8.2.2 ALLIANCES ESTABLISHMENTS
5.8.3 STATUS ACCREDITATION (INCLUDING MFTN)
5.8.4 DOMESTIC COURSE OF CORRECTION
5.8.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS
5.8.4.2 ESTABLISHMENT OF SEZS/INDUSTRIAL PARKS
6 REGULATION COVERAGE
6.1 PRODUCT CODES
6.2 CERTIFIED STANDARDS
6.3 SAFETY STANDARDS
6.3.1 MATERIAL HANDLING & STORAGE
6.3.2 TRANSPORT & PRECAUTIONS
6.3.3 HAZARD IDENTIFICATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN GASTROINTESTINAL BLEEDING CASES
7.1.2 AGING POPULATION DRIVING INCREASED DEMAND FOR GI DISORDERS
7.1.3 ADOPTION OF MINIMALLY INVASIVE ENDOSCOPIC PROCEDURES
7.1.4 RISING AWARENESS AND EXPANDED SCREENING PROGRAMS FOR GASTROINTESTINAL ENDOSCOPY
7.2 RESTRAINTS
7.2.1 HIGH COST AND TECHNICAL COMPLEXITY OF ENDOSCOPIC HEMOSTASIS DEVICES
7.2.2 LIMITED AWARENESS IN LOW-INCOME COUNTRIES
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN HEMOSTASIS DEVICES
7.3.2 EXPANSION IN EMERGING MARKETS (ASIA-PACIFIC, LATIN AMERICA)
7.3.3 GROWING ADOPTION OF HOME-BASED AND CAPSULE ENDOSCOPY SOLUTIONS
7.4 CHALLENGES
7.4.1 REIMBURSEMENT ISSUES FOR ENDOSCOPIC PROCEDURES
7.4.2 COMPLEXITIES IN ENDOSCOPE REPROCESSING AND STERILIZATION PROCESSES
8 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 MECHANICAL HEMOSTASIS DEVICES
8.2.1 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
8.2.1.1 HEMOSTATIC CLIPS
8.2.1.1.1 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE
8.2.1.1.1.1 THROUGH-THE-SCOPE (TTS) CLIPS
8.2.1.1.1.2 OVER-THE-SCOPE (OTS) CLIPS
8.2.1.1.2 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL
8.2.1.1.2.1 STAINLESS STEEL
8.2.1.1.2.2 TITANIUM
8.2.1.2 BANDING DEVICES
8.2.1.2.1 BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE
8.2.1.2.1.1 VARICEAL BANDING KITS
8.2.1.2.1.2 OESOPHAGEAL BANDING DEVICES
8.2.1.3 HEMOSTATIC FORCEPS
8.2.1.4 OTHERS
8.2.2 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.2.2.1 NORTH AMERICA
8.2.2.2 EUROPE
8.2.2.3 ASIA-PACIFIC
8.2.2.4 SOUTH AMERICA
8.2.2.5 MIDDLE EAST & AFRICA
8.3 THERMAL DEVICES
8.3.1 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
8.3.1.1 ARGON PLASMA COAGULATORS
8.3.1.2 HEATER PROBES
8.3.1.3 BIPOLAR COAGULATION DEVICES
8.3.1.3.1 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE
8.3.1.3.1.1 MONOPOLAR
8.3.1.3.1.2 BIPOLAR
8.3.1.3.2 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION
8.3.1.3.2.1 UPPER GI BLEEDING
8.3.1.3.2.2 LOWER GI BLEEDING
8.3.1.4 OTHERS
8.3.2 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.3.2.1 NORTH AMERICA
8.3.2.2 EUROPE
8.3.2.3 ASIA-PACIFIC
8.3.2.4 SOUTH AMERICA
8.3.2.5 MIDDLE EAST & AFRICA
8.4 TOPICAL AGENTS AND INJECTABLES
8.4.1 TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
8.4.1.1 EPINEPHRINE INJECTION
8.4.1.2 HEMOSTATIC SPRAY (POWDER)
8.4.1.3 HEMOSTATIC GELS
8.4.1.4 FIBRIN SEALANTS
8.4.1.5 SCLEROSING AGENTS
8.4.2 TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.4.2.1 NORTH AMERICA
8.4.2.2 EUROPE
8.4.2.3 ASIA-PACIFIC
8.4.2.4 SOUTH AMERICA
8.4.2.5 MIDDLE EAST & AFRICA
8.5 OTHERS
8.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
8.5.1.1 NORTH AMERICA
8.5.1.2 EUROPE
8.5.1.3 ASIA-PACIFIC
8.5.1.4 SOUTH AMERICA
8.5.1.5 MIDDLE EAST & AFRICA
9 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE
9.1 OVERVIEW
9.2 UPPER GASTROINTESTINAL ENDOSCOPY
9.2.1 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
9.2.1.1 BLEEDING ULCER MANAGEMENT
9.2.1.2 VARICEAL BLEEDING
9.2.1.3 DIEULAFOY LESION
9.2.2 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.2.2.1 NORTH AMERICA
9.2.2.2 EUROPE
9.2.2.3 ASIA-PACIFIC
9.2.2.4 SOUTH AMERICA
9.2.2.5 MIDDLE EAST & AFRICA
9.3 LOWER GASTROINTESTINAL ENDOSCOPY
9.3.1 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
9.3.1.1 COLONIC BLEEDING
9.3.1.2 DIVERTICULAR BLEEDING
9.3.2 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.3.2.1 NORTH AMERICA
9.3.2.2 EUROPE
9.3.2.3 ASIA-PACIFIC
9.3.2.4 SOUTH AMERICA
9.3.2.5 MIDDLE EAST & AFRICA
9.4 BRONCHOSCOPIC HEMOSTASIS
9.4.1 BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.4.1.1 NORTH AMERICA
9.4.1.2 EUROPE
9.4.1.3 ASIA-PACIFIC
9.4.1.4 SOUTH AMERICA
9.4.1.5 MIDDLE EAST & AFRICA
9.5 OTHERS
9.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
9.5.1.1 NORTH AMERICA
9.5.1.2 EUROPE
9.5.1.3 ASIA-PACIFIC
9.5.1.4 SOUTH AMERICA
9.5.1.5 MIDDLE EAST & AFRICA
10 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 GASTROINTESTINAL BLEEDING
10.2.1 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
10.2.1.1 PEPTIC ULCER BLEEDING
10.2.1.2 ESOPHAGEAL VARICES
10.2.1.3 COLORECTAL CANCERS
10.2.2 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
10.2.2.1 MECHANICAL HEMOSTASIS DEVICES
10.2.2.2 THERMAL DEVICES
10.2.2.3 TOPICAL AGENTS AND INJECTABLES
10.2.2.4 OTHERS
10.2.3 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
10.2.3.1 NORTH AMERICA
10.2.3.2 EUROPE
10.2.3.3 ASIA-PACIFIC
10.2.3.4 SOUTH AMERICA
10.2.3.5 MIDDLE EAST & AFRICA
10.3 NON-GASTROINTESTINAL BLEEDING
10.3.1 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
10.3.1.1 NASAL BLEEDING (EPISTAXIS)
10.3.1.2 POST-SURGICAL BLEEDING
10.3.2 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
10.3.2.1 MECHANICAL HEMOSTASIS DEVICES
10.3.2.2 THERMAL DEVICES
10.3.2.3 TOPICAL AGENTS & INJECTABLES
10.3.2.4 OTHERS
10.3.3 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.3.3.1 NORTH AMERICA
10.3.3.2 EUROPE
10.3.3.3 ASIA-PACIFIC
10.3.3.4 SOUTH AMERICA
10.3.3.5 MIDDLE EAST & AFRICA
10.4 TRAUMA MANAGEMENT
10.4.1 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
10.4.1.1 MECHANICAL HEMOSTASIS DEVICES
10.4.1.2 THERMAL DEVICES
10.4.1.3 TOPICAL AGENTS & INJECTABLES
10.4.1.4 OTHERS
10.4.2 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
10.4.2.1 NORTH AMERICA
10.4.2.2 EUROPE
10.4.2.3 ASIA-PACIFIC
10.4.2.4 SOUTH AMERICA
10.4.2.5 MIDDLE EAST & AFRICA
10.5 OTHERS
10.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
10.5.1.1 NORTH AMERICA
10.5.1.2 EUROPE
10.5.1.3 ASIA-PACIFIC
10.5.1.4 SOUTH AMERICA
10.5.1.5 MIDDLE EAST & AFRICA
11 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE
11.2.1.1 PUBLIC
11.2.1.2 PRIVATE
11.2.2 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.2.2.1 NORTH AMERICA
11.2.2.2 EUROPE
11.2.2.3 ASIA-PACIFIC
11.2.2.4 SOUTH AMERICA
11.2.2.5 MIDDLE EAST & AFRICA
11.3 AMBULATORY SURGERY CENTERS
11.3.1 AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.3.1.1 NORTH AMERICA
11.3.1.2 EUROPE
11.3.1.3 ASIA-PACIFIC
11.3.1.4 SOUTH AMERICA
11.3.1.5 MIDDLE EAST & AFRICA
11.4 SPECIALTY CLINICS
11.4.1 SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.4.1.1 NORTH AMERICA
11.4.1.2 EUROPE
11.4.1.3 ASIA-PACIFIC
11.4.1.4 SOUTH AMERICA
11.4.1.5 MIDDLE EAST & AFRICA
11.5 OTHERS
11.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
11.5.1.1 NORTH AMERICA
11.5.1.2 EUROPE
11.5.1.3 ASIA-PACIFIC
11.5.1.4 SOUTH AMERICA
11.5.1.5 MIDDLE EAST & AFRICA
12 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 INDIRECT SALES
12.2.1 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE
12.2.1.1 OFFLINE
12.2.1.2 ONLINE
12.2.2 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
12.2.2.1 NORTH AMERICA
12.2.2.2 EUROPE
12.2.2.3 ASIA-PACIFIC
12.2.2.4 SOUTH AMERICA
12.2.2.5 MIDDLE EAST & AFRICA
12.3 DIRECT SALES
12.3.1 DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
12.3.1.1 NORTH AMERICA
12.3.1.2 EUROPE
12.3.1.3 ASIA-PACIFIC
12.3.1.4 SOUTH AMERICA
12.3.1.5 MIDDLE EAST & AFRICA
13 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 FRANCE
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 NETHERLANDS
13.1.7 BELGIUM
13.1.8 SWITZERLAND
13.1.9 SWEDEN
13.1.10 DENMARK
13.1.11 NORWAY
13.1.12 FINLAND
13.1.13 RUSSIA
13.1.14 TURKEY
13.1.15 REST OF EUROPE
14 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES MANUFACTURERS
16.1 OLYMPUS CORPORATION
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 BOSTON SCIENTIFIC CORPORATION
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 CONMED CORPORATION
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 MEDTRONIC
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 COOK
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 ANKAFERD
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVEOPMENT
16.7 B. BRAUN SE
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVEOPMENT
16.8 CREO MEDICAL GMBH
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DIVERSATEK, INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVEOPMENT
16.1 DUOMED GROUP
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVEOPMENT
16.11 ENDOCLOT PLUS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVEOPMENT
16.12 ERBE ELEKTROMEDIZIN GMBH
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 FUJIFILM HOLDINGS CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 JOHNSON & JOHNSON (ETHICON)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVEOPMENT
16.15 KARL STORZ SE & CO. KG, TUTTLINGEN
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVEOPMENT
16.16 MEDITALIA S.R.L.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 MICRO-TECH ENDOSCOPY
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 MTW ENDOSKOPIE MANUFAKTU
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVEOPMENT
16.19 OVESCO ENDOSCOPY AG
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVEOPMENT
16.2 PENTAX MEDICAL
16.20.1 COMPANY SNAPSHOT
16.20.2 SOLUTION PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 STERIS
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT
17 COMPANY PROFILES DISTRIBUTOR
17.1 BOSTON IVY HEALTHCARE SOLUTIONS PRIVATE LIMITED
17.1.1 COMPANY SNAPSHOT
17.1.2 PRODUCT PORTFOLIO
17.1.3 RECENT DEVELOPMENT
17.2 CARDINAL HEALTH
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVEOPMENT
17.3 HENRY SCHEIN, INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVEOPMENT
17.4 MCKESSON MEDICAL-SURGICAL INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 PRODUCT PORTFOLIO
17.4.3 RECENT DEVEOPMENT
17.5 MFI MEDICAL
17.5.1 COMPANY SNAPSHOT
17.5.2 PRODUCT PORTFOLIO
17.5.3 RECENT DEVEOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tabela
TABLE 1 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 2 EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 3 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 4 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 5 EUROPE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 6 EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 7 EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 8 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 9 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 10 EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 11 EUROPE TOPICAL AGENTS & INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 12 EUROPE TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 13 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 14 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 15 EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 17 EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 18 EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 19 EUROPE BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 20 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 21 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 22 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 23 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 24 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 25 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 27 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 28 EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 29 EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 30 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 31 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 32 EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 33 EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 34 EUROPE AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 35 EUROPE SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 36 EUROPE OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 37 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 38 EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 40 EUROPE DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 41 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 42 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 43 EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 45 EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 46 EUROPE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 47 EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 50 EUROPE TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 51 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 52 EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 54 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 55 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 56 EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 57 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 58 EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 59 EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 60 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 61 EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 63 EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 64 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 65 GERMANY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 GERMANY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 67 GERMANY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 68 GERMANY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 69 GERMANY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 70 GERMANY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 71 GERMANY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 72 GERMANY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 73 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 74 GERMANY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 75 GERMANY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 76 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 77 GERMANY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 78 GERMANY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 79 GERMANY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 GERMANY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 81 GERMANY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 82 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 83 GERMANY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 84 GERMANY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 85 GERMANY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 86 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 87 U.K. MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 88 U.K. HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 89 U.K. HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 90 U.K. BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 91 U.K. THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 U.K. BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 93 U.K. BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 94 U.K. TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 95 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 96 U.K. UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 97 U.K. LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 98 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 99 U.K. GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 100 U.K. GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 U.K. NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 U.K. NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 103 U.K. TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 104 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 105 U.K. HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 106 U.K. ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 107 U.K. INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 109 FRANCE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 110 FRANCE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 111 FRANCE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 112 FRANCE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 FRANCE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 FRANCE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 FRANCE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 116 FRANCE TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 117 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 118 FRANCE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 119 FRANCE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 120 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 121 FRANCE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 122 FRANCE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 123 FRANCE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 124 FRANCE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 125 FRANCE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 126 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 127 FRANCE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 128 FRANCE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 129 FRANCE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 130 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 131 ITALY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 132 ITALY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 133 ITALY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 134 ITALY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 135 ITALY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 136 ITALY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 137 ITALY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 138 ITALY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 139 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 140 ITALY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 141 ITALY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 142 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 143 ITALY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 144 ITALY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 ITALY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 146 ITALY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 ITALY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 148 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 149 ITALY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 150 ITALY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 151 ITALY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 152 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 153 SPAIN MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 SPAIN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 SPAIN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 156 SPAIN BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 157 SPAIN THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 158 SPAIN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 159 SPAIN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 160 SPAIN TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 161 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 162 SPAIN UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 163 SPAIN LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 164 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 165 SPAIN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 166 SPAIN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 167 SPAIN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 168 SPAIN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 169 SPAIN TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 171 SPAIN HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 172 SPAIN ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 173 SPAIN INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 174 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 175 NETHERLANDS MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 176 NETHERLANDS HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 177 NETHERLANDS HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 178 NETHERLANDS BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 179 NETHERLANDS THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 NETHERLANDS BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 NETHERLANDS BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 182 NETHERLANDS TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 183 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 184 NETHERLANDS UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 185 NETHERLANDS LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 186 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 187 NETHERLANDS GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 188 NETHERLANDS GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 189 NETHERLANDS NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 NETHERLANDS NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 191 NETHERLANDS TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 192 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 193 NETHERLANDS HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 194 NETHERLANDS ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 195 NETHERLANDS INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 196 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 BELGIUM MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 198 BELGIUM HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 199 BELGIUM HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 200 BELGIUM BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 BELGIUM THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 202 BELGIUM BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 203 BELGIUM BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 204 BELGIUM TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 206 BELGIUM UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 207 BELGIUM LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 208 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 209 BELGIUM GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 210 BELGIUM GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 211 BELGIUM NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 212 BELGIUM NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 213 BELGIUM TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 214 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 215 BELGIUM HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 216 BELGIUM ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 217 BELGIUM INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 218 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 219 SWITZERLAND MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 220 SWITZERLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 SWITZERLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 222 SWITZERLAND BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 223 SWITZERLAND THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 224 SWITZERLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 225 SWITZERLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 226 SWITZERLAND TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 227 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 228 SWITZERLAND UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 SWITZERLAND LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 230 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 231 SWITZERLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 232 SWITZERLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 233 SWITZERLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 234 SWITZERLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 235 SWITZERLAND TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 236 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 237 SWITZERLAND HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 238 SWITZERLAND ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 239 SWITZERLAND INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 240 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 241 SWEDEN MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 242 SWEDEN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 243 SWEDEN HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 244 SWEDEN BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 SWEDEN THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 246 SWEDEN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 247 SWEDEN BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 248 SWEDEN TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 249 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 250 SWEDEN UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 251 SWEDEN LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 252 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 253 SWEDEN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 254 SWEDEN GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 255 SWEDEN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 256 SWEDEN NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 257 SWEDEN TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 258 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 259 SWEDEN HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 260 SWEDEN ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 261 SWEDEN INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 262 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 263 DENMARK MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 264 DENMARK HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 265 DENMARK HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 266 DENMARK BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 267 DENMARK THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 268 DENMARK BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 269 DENMARK BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 270 DENMARK TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 271 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 272 DENMARK UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 273 DENMARK LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 274 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 275 DENMARK GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 276 DENMARK GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 277 DENMARK NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 278 DENMARK NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 279 DENMARK TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 280 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 281 DENMARK HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 282 DENMARK ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 283 DENMARK INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 284 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 285 NORWAY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 286 NORWAY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 287 NORWAY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 288 NORWAY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 289 NORWAY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 290 NORWAY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 291 NORWAY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 292 NORWAY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 293 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 294 NORWAY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 295 NORWAY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 296 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 297 NORWAY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 298 NORWAY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 299 NORWAY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 300 NORWAY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 301 NORWAY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 302 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 303 NORWAY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 304 NORWAY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 305 NORWAY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 306 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 307 FINLAND MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 308 FINLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 309 FINLAND HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 310 FINLAND BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 311 FINLAND THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 312 FINLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 313 FINLAND BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 314 FINLAND TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 315 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 316 FINLAND UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 317 FINLAND LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 318 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 319 FINLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 320 FINLAND GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 321 FINLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 322 FINLAND NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 323 FINLAND TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 324 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 325 FINLAND HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 326 FINLAND ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 327 FINLAND INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 328 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 329 RUSSIA MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 330 RUSSIA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 331 RUSSIA HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 332 RUSSIA BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 333 RUSSIA THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 334 RUSSIA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 335 RUSSIA BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 336 RUSSIA TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 337 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 338 RUSSIA UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 339 RUSSIA LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 340 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 341 RUSSIA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 342 RUSSIA GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 343 RUSSIA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 344 RUSSIA NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 345 RUSSIA TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 346 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 347 RUSSIA HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 348 RUSSIA ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 349 RUSSIA INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 350 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 351 TURKEY MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 352 TURKEY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 353 TURKEY HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 354 TURKEY BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 355 TURKEY THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 356 TURKEY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 357 TURKEY BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 358 TURKEY TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 359 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 360 TURKEY UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 361 TURKEY LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 362 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 363 TURKEY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 364 TURKEY GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 365 TURKEY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 366 TURKEY NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 367 TURKEY TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 368 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 369 TURKEY HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 370 TURKEY ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 371 TURKEY INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 372 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 373 REST OF EUROPE MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 374 REST OF EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 375 REST OF EUROPE HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL, 2018-2033 (USD THOUSAND)
TABLE 376 REST OF EUROPE BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 377 REST OF EUROPE THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 378 REST OF EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE, 2018-2033 (USD THOUSAND)
TABLE 379 REST OF EUROPE BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 380 REST OF EUROPE TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 381 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE, 2018-2033 (USD THOUSAND)
TABLE 382 REST OF EUROPE UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 383 REST OF EUROPE LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 384 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)
TABLE 385 REST OF EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 386 REST OF EUROPE GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 387 REST OF EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 388 REST OF EUROPE NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 389 REST OF EUROPE TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)
TABLE 390 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 391 REST OF EUROPE HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 392 REST OF EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
TABLE 393 REST OF EUROPE INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE, 2018-2033 (USD THOUSAND)
Lista de Figura
FIGURE 1 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: SEGMENTATION
FIGURE 2 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COUNTRYWISE MARKET ANALYSIS
FIGURE 5 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: MULTIVARIATE MODELLING
FIGURE 8 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: SEGMENTATION
FIGURE 12 TWO SEGMENTS COMPRISE THE DOMINICAN REPUBLIC ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE
FIGURE 13 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: EXECUTIVE SUMMARY
FIGURE 14 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: STRATEGIC DECISIONS
FIGURE 15 RISING PREVALANCE OF ENDOSCOPIC HEMOSTASIS CASES EXPECTED TO DRIVE THE GROWTH OF THE EUROPE ENDOSCOPIC HEMOSTASIS MARKET FROM 2026 TO 2033
FIGURE 16 THE TYPE 2 ENDOSCOPIC HEMOSTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ENDOSCOPIC HEMOSTASIS MARKET IN 2026 & 2033
FIGURE 17 COMPANY EVALUATION QUADRANT
FIGURE 18 DROC ANALYSIS
FIGURE 19 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE, 2025
FIGURE 20 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , CAGR (2025-2032)
FIGURE 21 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , CAGR (2025-2032)
FIGURE 22 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PRODUCT TYPE , LIFELINE CURVE (2025-2032)
FIGURE 23 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE, 2025
FIGURE 24 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PROCEDURE , 2026-2033 (USD THOUSAND)
FIGURE 25 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY PROCEDURE , 2026-2033 (USD THOUSAND)
FIGURE 26 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION, 2025
FIGURE 27 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)
FIGURE 28 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)
FIGURE 29 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY APPLICATION, 2026-2033 (USD THOUSAND)
FIGURE 30 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY END USER, 2025
FIGURE 31 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 32 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 33 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY END USER, 2026-2033 (USD THOUSAND)
FIGURE 34 EUROPE ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL, 2025
FIGURE 35 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 36 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 37 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: BY DISTRIBUTION CHANNEL, 2026-2033 (USD THOUSAND)
FIGURE 38 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: SNAPSHOT (2025)
FIGURE 39 EUROPE ENDOSCOPIC HEMOSTASIS MARKET: COMPANY SHARE 2025 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
